Femara medication (Letrozole): price, usage, side effects, where to buy online
Femara (Letrozole) is also known as leetrozole It is only used in postmenopausal women. It is used in women with hormone-resistant breast cancer after surgery when it was first approved in 1997. It can also be used in women with advanced breast cancer, either as first-line treatment or after progression of tamoxifen, or in women with locally advanced or even metastatic breast cancer.
Price of Femara
Femara costs between $1.78 and $3.08 per pill. This depends on the size of the pack.
What is Femara (letrozole)?
Femara (letrozole) is a medicine used for the adjuvant treatment of hormone receptor positive early breast cancer in postmenopausal women, the continuation of adjuvant treatment of hormone-dependent early breast cancer in postmenopausal women who have received standard adjuvant treatment with tamoxifen for five years. Femara is a first-line treatment for advanced hormone-dependent breast cancer in postmenopausal, relapsed or advanced women who have received antiestrogens. Femara is prescribed when chemotherapy is not adequate or immediate surgery is not indicated.
Letrozole is administered orally, independent of food. The recommended dose in adult and elderly women is 2.5 milligrams/day as adjuvant therapy and as continuation adjuvant therapy is recommended for five years or until tumour relapse. In advanced or metastatic disease, treatment should be continued until tumour progression is evident. In adjuvant therapy, a sequential treatment regimen may be considered, Letrozole two years followed by Tamoxifen three years. In neoadjuvant treatment, continue treatment for four to eight months to establish tumour shrinkage.
Side effects of Letrozole may include weight gain, headache, dizziness, nausea, vomiting, dyspepsia, constipation, diarrhoea, increased sweating, alopecia, maculopapular, psoriasis, vesicular arthralgia, myalgia, bone pain, osteoporosis, bone fractures, decreased appetite, hypercholesterolemia, increased appetite, hot flashes, fatigue, peripheral edema, malaise, depression, hyperbilirubinemia, jaundice, chest pain, hyperhidrosis.
Warnings and Precautions
Letrozole is contraindicated during pregnancy and lactation, risk assessment of benefit in renal insufficiency, hepatic cell carcinoma, history of osteoporosis and/or fractures or increased risk of osteoporosis should be subject to bone mineral density assessment before, during and after treatment. Concurrent use of tamoxifen, other anti-estrogens or oestrogenic therapy should be avoided. Tendonitis and tendon rupture may occur with rare frequency. Patients should be closely monitored and appropriate measures taken. For example, immobilisation in those with an affected tendon.
Interactions with other drugs
Interactions of letrozole with other drugs, decreased plasma levels with tamoxifen, other anti-estrogens or estrogen-containing therapies, increased toxicity of other drugs. A similar effect on norethynodrel levels has been observed when using a lower dosage of letrozole. When used in combination with tamoxifen, letrozole may decrease the concentration of tamoxifen by approximately 25% and reduce its effectiveness. An interaction between letrozole and other anti-estrogens is unknown. Letrozole has been shown on a case-by-case basis to increase the toxicity of other drugs.